Loading
Bolt Biotherapeutics, Inc. Stock: price and insider trades · United States
2 insiders bought €3,825 of shares over the last 90 days, the latest filed 21 Sept 2026.
Cluster: 2 buyers in 30 daysBolt Biotherapeutics, Inc.: what insiders have been doing
Bolt Biotherapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 3 insiders published 16 filings.
Purchases and sales both appear in the filings: 6 purchases (2 insiders, €6,013) and 9 sales (3 insiders, €112k). Taken together, the sales exceed the purchases by €106k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €26k, the sale published on 21 September 2026 by Quinn William P. is the largest of the period (0.42% of market cap). On the buying side, the filings list 1 finance chief and 1 chief executive among the declarants.
Within a 30-day window, 6 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (21 September 2026) now reads 27 days. Typically, a trade is published a median of 5 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 16 filings in twelve months, the company is quieter than the median of 19 filings across the 5,808 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 11 purchases and 14 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
27
Thresholds
n/a
Buy Volume
€39,735
11 ops. · all time
Sell Volume
€2M
14 ops. · all time
Who traded when
BuySaleSarah Nemec4 buys3 sales
William P. Quinn4 buys3 sales
Grant Yonehiro3 sales
Since the insiders bought
- -15.0%Entry US$5.40 · Close at T+90 US$4.59
- -15.0%Entry US$5.40 · Close at T+90 US$4.59
- -60.5%Entry US$73.40 · Close at T+365 US$29.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.29
Analyst consensus
3 analystsUS$5.00Target US$29.00(+577%)US$75.00
Income statement
RevenueUS$7.7M
EBITDA-US$33.3M-433% margin
Net income-US$33.4M-433.7% margin
Valuation
PER (forward)-0.2x
P/Book0.7x
Beta1.01
Balance sheet & cash
Market capUS$8.3M
Total debtUS$23M
Free Cash Flow-US$39.9M
Debt / Equity171%
Profitability & ownership
ROE-111.6%
ROA-30.7%
% insiders3.5%
% institutions27.9%
Last declaration on 21 September 2026
Declarations27 total
4,909 shares@ US$3.31830.23% mcap37.2% of flowCommon StockSEC:0001193125-26-396894:1
6,850 shares@ US$3.23640.31% mcap50.6% of flowCommon StockSEC:0001193125-26-396894:2
9,132 shares@ US$3.23640.42% mcap34.8% of flowCommon StockSEC:0001193125-26-396890:3
637 shares@ US$3.8762.9% of flowCommon StockSEC:0001193125-26-396890:0
Canonical exit: 3 Sept 2026 (T+90)
1,889 shares@ US$3.7740.10% mcap8.3% of flowCommon StockSEC:0001193125-26-396890:1
6,545 shares@ US$3.31830.31% mcap25.6% of flowCommon StockSEC:0001193125-26-396890:2
509 shares@ US$3.8766.4% of flowCommon StockSEC:0001193125-26-396892:0
Canonical exit: 3 Sept 2026 (T+90)
843 shares@ US$3.7740.045% mcap10.3% of flowCommon StockSEC:0001193125-26-396892:1
2,922 shares@ US$3.31830.14% mcap31.7% of flowCommon StockSEC:0001193125-26-396892:2
4,077 shares@ US$3.23640.19% mcap43.1% of flowCommon StockSEC:0001193125-26-396892:3
1,417 shares@ US$3.7740.075% mcap12.1% of flowCommon StockSEC:0001193125-26-396894:0
125 shares@ US$4.6070.7% of flowCommon StockSEC:0001193125-26-037697:0
Canonical exit: 5 Mar 2026 (T+90)
125 shares@ US$4.6071.9% of flowCommon StockSEC:0001193125-26-037690:0
Canonical exit: 5 Mar 2026 (T+90)
30,000 shares0Common StockSEC:0001193125-25-250333:0
125 shares@ US$5.4922.2% of flowCommon StockSEC:0001193125-25-250334:0
Canonical exit: 4 Sept 2025 (T+90)
125 shares@ US$5.4920.8% of flowCommon StockSEC:0001193125-25-250332:0
Canonical exit: 4 Sept 2025 (T+90)
2,500 shares@ US$0.49651.6% of flowCommon StockSEC:0000950170-25-063840:0
Canonical exit: 16 Mar 2025 (T+90)
2,500 shares@ US$0.49654.4% of flowCommon StockSEC:0000950170-25-063846:0
Canonical exit: 16 Mar 2025 (T+90)
1,829 shares@ US$1.18152.7% of flowCommon StockSEC:0001209191-23-058458:0
Canonical exit: 4 Sept 2023 (T+90)
22,674 shares@ US$0.90669.8% of flowCommon StockSEC:0001209191-23-057049:0
1,707 shares@ US$0.9017.4% of flowCommon StockSEC:0001213900-23-089692:0
1,707 shares@ US$0.90145.3% of flowCommon StockSEC:0001209191-23-056548:0
7,531 shares@ US$0.9682.6% of flowCommon StockSEC:0001213900-23-088909:0
▼
Same trade as the filing by Vivo Capital VIII, LLC, counted once · View ↗
7,531 shares@ US$0.9624.9% of flowCommon StockSEC:0001209191-23-056185:0
800,000 shares@ US$2.00100.0% of flowCOMMON STOCKSEC:0001209191-22-042241:0
25 of 27 declarations
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a U.S.-listed clinical-stage biopharmaceutical company traded on NASDAQ in the United States. The company is focused on oncology immunotherapy, with a scientific strategy centered on myeloid biology and the reprogramming of the tumor microenvironment. Its core thesis is to combine the targeting precision of antibodies with the activating power of the innate and adaptive immune systems in order to create a more effective anti-cancer response.
The company was formed in its current structure in July 2015 and is headquartered in Redwood City, California, in the San Francisco Bay Area. Bolt’s platform is built around its proprietary Boltbody™ ISAC approach, short for Immune-Stimulating Antibody Conjugate. This platform is designed to deliver immune activation directly to tumors, which is why Bolt is positioned more as a next-generation immuno-oncology innovator than as a conventional antibody company. Over time, the company has refined its pipeline and in 2024 and 2025 sharpened its focus on a smaller number of programs in order to conserve capital and prioritize assets with the best clinical potential.
Read moreShow less
As of late 2025, Bolt’s main development assets are BDC-3042, a phase 1 dectin-2 agonist antibody, and BDC-4182, a next-generation Boltbody ISAC candidate targeting claudin 18.2. The company previously pursued trastuzumab imbotolimod, but this program was discontinued as part of a strategic pipeline prioritization. That shift is important for investors: it shows management is willing to exit non-core or lower-priority programs to preserve cash and concentrate on assets with stronger scientific and commercial promise.
From a competitive standpoint, Bolt operates in a crowded and capital-intensive oncology innovation landscape. It competes indirectly with large pharmaceutical companies, specialty biotech firms, and platform companies developing antibody-drug conjugates, immunostimulatory conjugates, and other advanced immunotherapies. Bolt’s differentiator is its myeloid-cell-focused biology and ISAC platform, which gives it a distinct niche but also exposes it to substantial development risk. The company does not yet have a commercial product portfolio; it remains dependent on clinical progress, collaboration income, and capital market access.
Geographically, Bolt’s operating base is primarily in the United States, although it established an Australian subsidiary in 2024 to broaden its research and development footprint. Recent notable events include the May 2024 restructuring and pipeline prioritization, the June 2025 one-for-twenty reverse stock split, and the October 2025 restructuring that reduced headcount to preserve cash. In the same October 2025 update, Bolt said it expected initial clinical data for BDC-4182 in the third quarter of 2026 and aimed to extend its cash runway into 2027. For investors, Bolt remains a high-risk, event-driven biotech story whose valuation will likely be driven by clinical readouts, financing needs, and execution on its narrowed pipeline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
